Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain

Kyle LaHucik

Senior Reporter

Boston biotech Axonis Therapeutics has raised a $115 million Series A to test whether its oral drug AXN-027 can help patients with focal epilepsy and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets

AstraZeneca China exec probed by local authorities

A startup backed by Nobel winner David Baker takes an AI twist on antibodies

Biogen signs molecular glue deal, raises yearly projections

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

GSK remains ‘very confident’ in RSV vaccine amid competition, sales slump

Ax­o­nis snags $115M to test oral drugs for epilep­sy and neu­ro­path­ic pain

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain